Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management. Monitored issues related to healthcare workforce shortages.
Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to Ambulatory Surgical Centers. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. Issues related to preventative services. Monitored issues related to pharmacy benefit management. Issues related to the Medicaid Drug Rebate Program. Monitored issues related to Medicare physician payment.
H.R.7024, Tax Relief for American Families and Workers Act of 2024, and issues related to the R&D tax credit.
Issues concerning bankruptcy reform.
H.R.2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024, H.R.4366, Consolidated Appropriations Act, 2024, and H.R.2882, Further Consolidated Appropriations Act, 2024, as they relate to drug pricing and SUPPORT Act.
Duration: February 1, 2019
to
present
General Issues: Health Issues , Medicare/Medicaid , Taxation/Internal Revenue Code , Bankruptcy , Budget/Appropriations , Government Issues , Consumer Issues/Safety/Protection , Law Enforcement/Crime/Criminal Justice
Spending: about $1,000,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2019: U.S. Senate, House of Representatives, Centers For Medicare and Medicaid Services (CMS), Office of Management & Budget (OMB), Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Stacey Hughes U.S. Senate Budget Cmte, Dpty Staff Dir;Ofce of the Asst. Maj. Ldr (Sen. Nickles), Policy Adv; Office of the Asst. Min. Ldr (Sen. Nickles), Policy Adv.;Senate Spec. Cmte on Aging (Sen.Cohen),Prof. Staff Member; U.S.Sen Connie Mack, Leg Asst/Schdlr
Don Nickles U.S. Senator
Emily Porter Ofce of Spkr(Rep.Boehner),Asst to Spkr,Policy;Ofce of Min. Ldr(Rep.Boehner),Plcy Adv;Ofce of the Maj. Ldr(Rep. Boehner),Plcy Adv;Cmte Ed & the Wrkfrc(Rep.Boehner),Coalitions Dir. for Educ Plcy; Rep.Trent Franks,Sr.Leg.Asst; Rep.Tom Tancredo,Leg.Asst
Don Kent U.S. Sen Ron Johnson, Chief of Staff; DHS Secretary Michael Chertoff, Asst Sec; DHS Secretary Tom Ridge, Deputy Asst Sec; U.S. Senate Budget Committee, Policy Adv; Office of the Asst. Maj. Leader Nickles Policy Adv.;U.S. Senator Don Nickles,Leg Asst
Mary Beth Savary Taylor Joint Economic Committee, General Counsel; U.S. Senator Connie Mack, Legislative Assistant
Greg D'Angelo White House Office of Management and Budget, Associate Director of Health Programs;
Senate Committee on the Budget (Sen. Gregg, Sen. Sessions, and Sen. Enzi), Professional Staff Member.
Brett Baker U.S. Senate Committee on Finance (Senators Crapo, Grassley, and Hatch)-Deputy Health Policy Director; Health Policy Dir.; Senior Policy Advsr; Policy Advisor. U.S. House of Representatives Committee on Ways and Means (Reps. Camp and Ryan) Prof. Staff
Jeff Choudhry U.S. Rep. Trent Franks, Legislative Director; U.S. Rep. Trent Franks, Legislative Assistant / Staff Assistant; House Small Business Committee, Intern
Rachel Jones Hensler n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $40,000. The report was filed on April 22.
Original Filing: 301574459.xml
Lobbying Issues
Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management. Monitored issues related to healthcare workforce shortages.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Issues related to Ambulatory Surgical Centers. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. Issues related to preventative services. Monitored issues related to pharmacy benefit management. Issues related to the Medicaid Drug Rebate Program. Monitored issues related to Medicare physician payment.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R.7024, Tax Relief for American Families and Workers Act of 2024, and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues concerning bankruptcy reform.
Lobbying Issues
H.R.2872, Further Additional Continuing Appropriations and Other Extensions Act, 2024, H.R.4366, Consolidated Appropriations Act, 2024, and H.R.2882, Further Consolidated Appropriations Act, 2024, as they relate to drug pricing and SUPPORT Act.
Agencies Lobbied
U.S. Senate
4th Quarter, 2023
In Q4, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $40,000. The report was filed on Jan. 19.
Original Filing: 301532445.xml
Lobbying Issues
Issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management. Monitored issues related to healthcare workforce shortages.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to insulin. Issues related to Ambulatory Surgical Centers. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. Amputation Reduction and Compassion Act. Monitored issues related to pharmacy benefit management. Issues related to the Medicaid Drug Rebate Program. Monitored issues related to Medicare physician payment.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored S. 866, American Innovation and Jobs Act, H.R. 3938, Build It in America Act, and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
3rd Quarter, 2023
In Q3, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $40,000. The report was filed on Oct. 20, 2023.
Original Filing: 301512519.xml
Lobbying Issues
Monitored issues related to mental health. Issues related to SUPPORT Act reauthorization. Monitored S. 2333, Pandemic and All-Hazards Preparedness and Response Act (PAHPA) reauthorization. Issues related to pharmacy benefit management. Monitored issues related to healthcare workforce shortages.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to insulin. Issues related to Ambulatory Surgical Centers. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. Amputation Reduction and Compassion Act. Monitored issues related to pharmacy benefit management. Issues related to the Medicaid Drug Rebate Program.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored S. 866, American Innovation and Jobs Act, H.R. 3938, Build It in America Act, and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
2nd Quarter, 2023
In Q2, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $40,000. The report was filed on July 20, 2023.
Original Filing: 301490633.xml
Lobbying Issues
Issues related to mental health. Issues related to Support Act implementation. Monitored Pandemic All Hazards Preparedness Act (PAHPA) reauthorization. Support Act reauthorization. Monitored issues related to pharmacy benefit management. Monitored issues related to healthcare workforce shortages.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing. Monitored issues related to insulin. Issues related to Ambulatory Surgical Centers. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act. Amputation Reduction and Compassion Act. Monitored issues related to pharmacy benefit management.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored S. 866, American Innovation and Jobs Act, H.R. 3938, Build It in America Act, and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
1st Quarter, 2023
In Q1, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 20, 2023.
Original Filing: 301462349.xml
Lobbying Issues
Issues related to mental health. Issues related to Support Act implementation. Monitored PAHPA reauthorization, Support Act Reauthorization and workforce shortages issues. Monitored issues related to pharmacy benefit management. Issues related to the implementation of the Lorna Breen Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to drug pricing issues. Monitored issues related to insulin.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored S. 866, American Innovation and Jobs Act and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
4th Quarter, 2022
In Q4, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 20, 2023.
Original Filing: 301440160.xml
Lobbying Issues
Monitored issues related to COVID relief. Issues related to mental health. S. 4348, FDASLA Act of 2022. H.R. 7667, Food and Drug Amendments of 2022. Issues related to clinical trial diversity. Monitored S.3799, The PREVENT Pandemic Act. H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to the FDA modernization including clinical trial diversity, accelerated approval, mental health and public health preparedness and response.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6007, Expansion of Coverage of Vaccines under Part B of the Medicare Program. Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to drug pricing issues. Monitored S. 3700 / H.R. 6833, Affordable Insulin Now Act. Monitored issues related to H.R. 3173, the Improving Seniors' Timely Access to Care Act. H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023, as it relates to Medicare physician payment and mental health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored implementation of H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to corporate taxes. Monitored H.R. 2617 (P.L. 117-328), the Consolidated Appropriations Act of 2023; H.R. 1304, the American Innovation and R&D Competitiveness Act; S. 749, the American Innovation and Jobs Act; and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
3rd Quarter, 2022
In Q3, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 20, 2022.
Original Filing: 301416336.xml
Lobbying Issues
Monitored issues related to COVID relief. Issues related to mental health. S. 4348, FDASLA Act of 2022. H.R. 7667, Food and Drug Amendments of 2022. Issues related to clinical trial diversity. Monitored S.3799, The PREVENT Pandemic Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6007, Expansion of Coverage of Vaccines under Part B of the Medicare Program. Drug pricing issues related to H.R. 5376 (P.L. 117-169), the Inflation Reduction Act. Issues concerning mental health. Monitored S. 3700 / H.R. 6833, Affordable Insulin Now Act. Monitored issues related to H.R. 3173, the Improving Seniors' Timely Access to Care Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored H.R. 5376 (P.L. 117-169), the Inflation Reduction Act, as it relates to corporate taxes. Monitored H.R. 1304, the American Innovation and R&D Competitiveness Act; S. 749, the American Innovation and Jobs Act; and issues related to the R&D tax credit.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
2nd Quarter, 2022
In Q2, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 19, 2022.
Original Filing: 301387333.xml
Lobbying Issues
Monitored issues related to COVID relief. Issues related to mental health. S. 4348, FDASLA Act of 2022. H.R. 7667, Food and Drug Amendments of 2022. Issues related to clinical trial diversity. Monitored S.3799, The PREVENT Pandemic Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6007, Expansion of Coverage of Vaccines under Part B of the Medicare Program. Issues related to maternal health. Issues related to COVID relief. Monitored drug pricing issues related to H.R. 5376, The Build Back Better Act. Issues concerning mental health. Monitored S. 3700 / H.R. 6833, Affordable Insulin Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act, as it relates to corporate taxes. Monitored S. 4218, Support Ukraine Through Our Tax Code Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues regarding COVID relief. Issues related to mental health. Issues related to FDA user fee agreements. H.R. 6007, Expansion of Coverage of Vaccines under Part B of the Medicare Program. Issues related to maternal health. Monitored drug pricing issues related to H.R. 5376, The Build Back Better Act. Monitored H.R. 6833, Affordable Insulin Now Act. Issues related to diversity in clinical trials, including H.R. 5030, DIVERSE Trials Act. Monitored issues related to H.R. 3173, Improving Seniors Timely Access to Care Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
1st Quarter, 2022
In Q1, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 12, 2022.
Original Filing: 301345223.xml
Lobbying Issues
Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID relief. Issues regarding COVID relief. Issues related to mental health. Issues related to FDA user fee agreements. Issues related to clinical trial diversity. S.3799, The PREVENT Pandemic Act and issues regarding pandemic preparedness.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6007, Expansion of Coverage of Vaccines under Part B of the Medicare Program. Issues related to maternal health. Issues related to COVID relief. Monitored drug pricing issues related to H.R. 5376, The Build Back Better Act. Issues concerning mental health. Monitored S. 3700 / H.R. 6833, Affordable Insulin Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act, as it relates to corporate taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID relief. Issues regarding COVID relief. Issues related to mental health. Issues related to FDA user fee agreements. H.R. 6007, Expansion of Coverage of Vaccines under Part B of the Medicare Program. Issues related to maternal health. Monitored drug pricing issues related to H.R. 5376, The Build Back Better Act. Monitored H.R. 6833, Affordable Insulin Now Act. Issues related to diversity in clinical trials, including H.R. 5030, DIVERSE Trials Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
4th Quarter, 2021
In Q4, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 18, 2022.
Original Filing: 301324773.xml
Lobbying Issues
Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID relief. Issues related to maternal health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 6007, Expansion of Coverage of Vaccines under Part B of the Medicare Program. Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID relief. Issues related to maternal health. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 5376, The Build Back Better Act, and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 3684 (P.L. 117-58), The Infrastructure Investment and Jobs Act, as it relates to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 5376, the Build Back Better Act, as it relates to corporate taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored S.Con.Res.14, FY 2022 Budget Resolution.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of vaccines. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 5376, The Build Back Better Act, and H.R. 19, the Lower Costs, More Cures Act. Monitored H.R. 3684 (P.L. 117-58), The Infrastructure Investment and Jobs Act, as it relates to drug pricing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 4777/S. 2497, the Nondebtor Release Prohibition Act and issues concerning bankruptcy reform.
3rd Quarter, 2021
In Q3, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308624.xml
Lobbying Issues
Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID relief. Issues related to maternal health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of vaccines. Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID relief. Issues related to maternal health. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 5376, The Build Back Better Act, and H.R. 19/S. 2164, the Lower Costs, More Cures Act. Monitored H.R. 3684, The Infrastructure Investment and Jobs Act, as it relates to drug pricing.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored the American Jobs Plan, as it relates to corporate and international taxes
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored S.Con.Res.14, FY 2022 Budget Resolution, as it relates to drug pricing and S.2428, The False Claims Amendments Act of 2021.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of vaccines. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act, H.R. 5376, The Build Back Better Act, and H.R. 19, the Lower Costs, More Cures Act. Monitored H.R. 3684, The Infrastructure Investment and Jobs Act, as it relates to drug pricing.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
S. 1425, Stop STALLING Act, S. 1428, Preserve Access to Affordable Generics and Biosimilars Act, S. 1388, Prescription Pricing for the People Act of 2021, and S. 1435, Affordable Prescriptions for Patients Act of 2021.
Type of Issue
Consumer Issues/Safety/Protection
2nd Quarter, 2021
In Q2, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 20, 2021.
Original Filing: 301285459.xml
Lobbying Issues
Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID relief. Issues related to maternal health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of vaccines. Monitored implementation of P.L. 117-2, the American Rescue Plan, as it relates to COVID relief. Issues related to maternal health. Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19/S. 2164, the Lower Costs, More Cures Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored the American Jobs Plan, as it relates to corporate and international taxes
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored FY 2022 Budget Resolution.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored drug pricing issues related to H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, the Lower Costs, More Cures Act.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 19, 2021.
Original Filing: 301259035.xml
Lobbying Issues
Monitored issues related to P.L. 117-2, the American Rescue Plan, as it relates to COVID relief.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to Medicare coverage of vaccines. Monitored P.L. 117-2, the American Rescue Plan, as it relates to drug pricing provisions and COVID relief and issues related to maternal health.
Agencies Lobbied
U.S. Senate
Lobbying Issues
American Jobs Plan, as it relates to corporate taxes.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitored FY'21 Budget Resolution.
Agencies Lobbied
U.S. Senate
4th Quarter, 2020
In Q4, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 21, 2021.
Original Filing: 301245052.xml
Lobbying Issues
Monitored issues related to S. 1895, Lower Health Care Costs Act of 2019; monitored issues related to P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); issues related to maternal mortality.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting; issues related to Medicare coverage of vaccines; issues related to H.R. 133, the Consolidated Appropriations Act of 2021, including vaccines, ASP reporting and liability. Monitored issues related to Most Favored Nation (MFN) rule and drug rebates.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor implementation of The Tax Cut and Jobs Act, as it relates to corporate tax and the taxation of U.S. multinational corporations. H.R. 133, the Consolidated Appropriations Act of 2021, as it relates to tax extenders.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Issues related to H.R. 133, the Consolidated Appropriations Act of 2021, including ASP reporting. S. 2543, Prescription Drug Pricing Reduction Act of 2019, as it relates to ASP reporting.
3rd Quarter, 2020
In Q3, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 20, 2020.
Original Filing: 301221940.xml
Lobbying Issues
Monitored issues related to S. 1895, Lower Health Care Costs Act of 2019; monitored issues related to P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); issues related to maternal mortality; H.R. 925 / H.R. 8406, The HEROES Act and The Health, Economic Assistance, Liability Protection and Schools (HEALS) Act and issues related to vaccines and liability; issues related to the Executive Order on Lowering Drug Prices by Putting America First.
Agencies Lobbied
U.S. Senate
Lobbying Issues
S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting; issues related to Medicare coverage of vaccines.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to H.R. 7120, the George Floyd Justice in Policing Act, and S. 3985, the JUSTICE Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
2nd Quarter, 2020
In Q2, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 17, 2020.
Original Filing: 301190919.xml
Lobbying Issues
Issues related to drug pricing; monitored issues related to S. 1895, Lower Health Care Costs Act of 2019; monitored issues related to P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); issues related to maternal mortality; issues related to vaccines and liability.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to biosimilars; S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitored issues related to H.R. 7120, the George Floyd Justice in Policing Act, and S. 3985, the JUSTICE Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Law Enforcement/Crime/Criminal Justice
1st Quarter, 2020
In Q1, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on April 17, 2020.
Original Filing: 301169599.xml
Lobbying Issues
Issues related to drug pricing and transparency; issues related to S. 1895, Lower Health Care Costs Act of 2019; S. 340, CREATES Act of 2019; issues related to the regulation of cosmetics; monitored issues related to P.L. 116-136, Coronavirus Aid, Response, and Economic Security Act (CARES Act); issues related to maternal mortality.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars; S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1158, the Consolidated Appropriations Act of 2020 and H.R. 1865, Further Consolidated Appropriations Act, 2020.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Jan. 21, 2020.
Original Filing: 301127418.xml
Lobbying Issues
Issues related to drug pricing and transparency; issues related to S. 1895, Lower Health Care Costs Act of 2019; S. 340, CREATES Act of 2019; issues related to the regulation of cosmetics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars; H.R. 2296, the METRIC Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting; H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 1158, the Consolidated Appropriations Act of 2020 and H.R. 1865, Further Consolidated Appropriations Act, 2020.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2019
In Q3, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on Oct. 21, 2019.
Original Filing: 301076475.xml
Lobbying Issues
Issues related to drug pricing and transparency; issues related to S. 1895, Lower Health Care Costs Act of 2019; S. 340, CREATES Act of 2019; issues related to the regulation of cosmetics.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to biosimilars; H.R. 2296, the METRIC Act; S. 2543, Prescription Drug Pricing Reduction Act of 2019, issues related to ASP reporting.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2019
In Q2, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $50,000. The report was filed on July 22, 2019.
Original Filing: 301057564.xml
Lobbying Issues
Issues related to drug pricing and transparency; issues related to part B drugs; issues related to international pricing; issues related to S. 1895, Lower Health Care Costs Act of 2019; S. 340, CREATES Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing; issues related to H.R. 2113, Prescription Drug STAR Act; issues related to biosimilars.
Agencies Lobbied
U.S. Senate
1st Quarter, 2019
In Q1, THE NICKLES GROUP, LLC lobbied for Johnson & Johnson Services, Inc. , earning $40,000. The report was filed on April 17, 2019.
Original Filing: 301027150.xml
Lobbying Issues
Issues related to drug pricing and transparency.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to drug pricing.
Agencies Lobbied
U.S. Senate
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...